The National Cancer Control Programme (NCCP) Technology Review Committee was established in March 2011 and is responsible for reviewing proposals received from industry or expert groups in Ireland for funding of new cancer drugs, or expanded indications for existing cancer drugs or related predictive laboratory tests. The recommendations are based on the degree of clinical effectiveness, the acute and chronic toxicity and the cost effectiveness of the proposed technology.
Information on the NCCP Technology Review Committee is available by clicking on the attached document.
NCCP Technology Review Committee.pdf (size 81.2 KB)
Details of new drugs recommended for reimbursement by the NCCP Technology Review Committee to the HSE Drug Committee are available here.